Charles River Laboratories International (CRL) Non-Current Deferred Tax Liability (2016 - 2025)
Charles River Laboratories International has reported Non-Current Deferred Tax Liability over the past 14 years, most recently at $95.2 million for Q4 2025.
- Quarterly results put Non-Current Deferred Tax Liability at $95.2 million for Q4 2025, down 10.99% from a year ago — trailing twelve months through Dec 2025 was $95.2 million (down 10.99% YoY), and the annual figure for FY2025 was $95.2 million, down 10.99%.
- Non-Current Deferred Tax Liability for Q4 2025 was $95.2 million at Charles River Laboratories International, down from $123.0 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for CRL hit a ceiling of $420.6 million in Q4 2021 and a floor of $95.2 million in Q4 2025.
- Median Non-Current Deferred Tax Liability over the past 5 years was $193.7 million (2022), compared with a mean of $193.6 million.
- Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 30.12% in 2021 and later plummeted 48.74% in 2022.
- Charles River Laboratories International's Non-Current Deferred Tax Liability stood at $420.6 million in 2021, then plummeted by 48.74% to $215.6 million in 2022, then dropped by 11.24% to $191.3 million in 2023, then plummeted by 44.1% to $107.0 million in 2024, then fell by 10.99% to $95.2 million in 2025.
- The last three reported values for Non-Current Deferred Tax Liability were $95.2 million (Q4 2025), $123.0 million (Q3 2025), and $109.3 million (Q2 2025) per Business Quant data.